A U.S. Food and Drug Administration (FDA) committee has voted in favor of Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat high-risk smoldering multiple myeloma…

BCB-276, an experimental cell therapy that Brainchild Bio is developing for diffuse intrinsic pontine glioma (DIPG), has been named a regenerative medicine advanced…

Treatment with pembrolizumab — an immune-modulating therapy sold for some cancers under the brand name Keytruda — improved survival among people with platinum-resistant ovarian cancer…

ELVN-001, an experimental treatment for chronic myeloid leukemia (CML), a type of blood cancer, is showing promising proof-of-concept effects for killing cancer cells in patients…

Adding the experimental therapy elraglusib to standard chemotherapy led to statistically significant improvements in survival for people with metastatic pancreatic ductal adenocarcinoma (PDAC), a form…

Optieum Biotechnologies and Genezen are teaming up to help develop OPTF01, an experimental cell therapy for glioblastoma, an aggressive form of glioma.

The use of testosterone as part of gender-affirming care does not increase the risk of gynecological cancers in transgender men or gender-diverse people, a study…

The U.S. Food and Drug Administration (FDA) has granted fast track status to ISB 2001, an experimental therapy for difficult-to-treat multiple myeloma. The designation…

Thursday is World Ovarian Cancer Day, an annual effort to raise awareness about ovarian cancer, the second most common type of gynecological cancer.

Each May marks Brain Tumor Awareness Month, with annual efforts to raise awareness about glioma and other types of cancer that affect the brain.